Evidence map›Paper›PMID 40204670›Full record

ReviewEuropean journal of heart failure2025

Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document.

Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T Abraham and 6 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Biykem BozkurtBaylor College of Medicine, Houston, TX, USA.
Wilfried MullensZiekenhuis Oost Limburg, Genk, Belgium.
Christophe LeclercqUniversity of Rennes, Rennes, France.
Andrea M RussoCooper Medical School of Rowan University, Camden, NJ, USA.
Gianluigi SavareseKarolinska Institutet, Stockholm, Sweden.
Michael BöhmSaarland University, Homburg, Germany.
Loreena HillQueen's University of Belfast, Belfast, UK.
Koichiro KinugawaUniversity of Toyama, Toyama, Japan.
Naoki SatoKawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan.
William T AbrahamOhio State University School of Medicine, Columbus, OH, USA.
Antoni Bayes-GenisAutonomous University of Barcelona, CIBERCV, Barcelona, Spain.
Alexandre MebazaaUniversité Paris Cité, MASCOT Inserm Unit, APHP, Paris, France.
Giuseppe M C RosanoDepartment of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy.
Shelley ZierothMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Cecilia LindeKarolinska Institutet, Stockholm, Sweden.
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision-making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices are frequently referred too late or not at all. Misconceptions about device therapy and the notion that the needs of patients (especially the prevention of sudden cardiac death) can now be met by expanding drug therapies may play a role in these disparities. This state-of-the-art review is produced by members of the DIRECT HF initiative, a patient-centred, expert-led educational programme that aims to advance guideline-directed use of CRM devices in patients with HFrEF. This review discusses the latest evidence on the role of CRM devices in reducing HFrEF mortality and morbidity, and provides practical guidance on patient referral, device selection, implant timing and patient-centred follow-up.

Indexed as

Cardiac Resynchronization TherapyConsensusDefibrillators, ImplantableHeart FailureStroke VolumeEuropeHumansCardiac dyssynchronyCardiac implantable electronic deviceCardiac resynchronization therapyImplantable cardioverter‐defibrillatorPatient‐centred heart failure careSudden cardiac death

Identifiers

PMID40204670
PMCPMC12370598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.